When co-administered with clinically approved drugs such as trastuzumab (TZ), trastuzumab-emtansine (T-DM1), or sacituzumab (SZ), AC-NKs exhibited significantly enhanced antitumor efficacy in HER2- and Trop-2-positive tumor models. This evidence concerns the gene TACSTD2 and neoplasm.